{"id":"W2003470917","doi":"10.2174/156800908786733450","title":"Anti-Angiogenic Targets in the Treatment of Advanced Renal Cell Carcinoma","year":2008,"lang":"en","type":"review","venue":"Current Cancer Drug Targets","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Canadian Institutes of Health Research; Health Canada; Memorial Sloan-Kettering Cancer Center","keywords":"Pazopanib; Temsirolimus; Sunitinib; Axitinib; Sorafenib; Everolimus; Medicine; Vascular endothelial growth factor; Cancer research; Renal cell carcinoma; Bevacizumab; Platelet-derived growth factor receptor; Angiogenesis; PI3K/AKT/mTOR pathway; Tyrosine-kinase inhibitor; Growth factor; Pharmacology; Internal medicine; Cancer; Biology; Signal transduction; VEGF receptors; Discovery and development of mTOR inhibitors; Receptor; Chemotherapy; Hepatocellular carcinoma","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000147578,0.001238377,0.003919643,0.0005582254,0.0001133499,0.00001515725,0.0005097659,0.0002414904,0.0001625576],"category_scores_gemma":[0.00001492072,0.0007401014,0.002216505,0.0008315026,0.0001912822,0.0000772718,0.00006461782,0.0005119179,0.00007767308],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001887717,"about_ca_system_score_gemma":0.001441223,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002556343,"about_ca_topic_score_gemma":0.00005874352,"domain_scores_codex":[0.9952867,0.0003913526,0.001454069,0.001107909,0.0008595969,0.0009003677],"domain_scores_gemma":[0.9971185,0.0002311916,0.0008938216,0.001329954,0.0001537847,0.0002727821],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00009543716,0.002959661,0.001369023,0.01257236,0.0003774599,0.000701787,0.002099203,0.00001973067,0.00001631044,0.000005076172,0.005521516,0.9742624],"study_design_scores_gemma":[0.002785999,0.000663529,0.001792998,0.005236323,0.002416053,0.0001564971,0.00005128332,0.000004273903,0.0008296036,0.000004326208,0.9854802,0.0005788764],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.01100677,0.9824006,0.000002097555,0.00006092109,0.001256636,0.004227939,0.0004013098,0.00003854488,0.0006051586],"genre_scores_gemma":[0.01232887,0.9834105,0.0001027491,0.00001965634,0.0006575613,0.001832558,0.001102444,0.0001383447,0.0004072752],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9799587,"threshold_uncertainty_score":0.999505,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05341450169617008,"score_gpt":0.340254233950875,"score_spread":0.2868397322547049,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}